NCT05994976 Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
| NCT ID | NCT05994976 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Innovaderm Research Inc. |
| Condition | Acne |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2023-10-17 |
| Primary Completion | 2028-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2023-10-17 with a primary completion date of 2028-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.
Eligibility Criteria
Inclusion Criteria: All subjects: 1. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures. 2. Subject must be willing to comply with all study procedures and must be available for the duration of the study. Healthy volunteers: 3. Male or female subject aged 18 years or older, at the time of consent. 4. Subject is in good general health, according to the investigator's judgment. Subjects with Acne: 5. Male or female subject aged 18 to 45 years old, inclusive, at the time of consent. Subjects with AD: 6. Male or female subject aged 18 years or older, at the time of consent. 7. Subject has clinically confirmed diagnosis of active AD, according to Hanifin and Rajka criteria. Subjects with CHE: 8. Male or female subject aged 18 years or older, at the time of consent. 9. Subject has at least a 6-month history of CHE before Screening (information obtained from medical chart or subject's physician, or directly from the subject). Subjects with HS: 10. Male or female subject aged 18 years or older, at the time of consent. 11. Subject has a clinically confirmed diagnosis of active HS with a disease duration of ≥ 6 months before screening as determined by the investigator through subject interview and/or review of the medical history. Subjects with PPP: 12. Male or female subject aged 18 years or older at the time of consent. 13. Subject has at least a 6-month history of PPP as defined by the presence of pustules on palms and/or soles, but without evidence of infection on palms and soles (information obtained from medical chart or subject's physician, or directly from the subject). Subjects with psoriasis: 14. Male or female subject aged 18 years or older, at the time of consent. Exclusion Criteria: All subjects: 1. Subject is a female who is pregnant or who is planning to become pregnant during the study. 2. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments.
Contact & Investigator
Robert Bissonnette, MD
PRINCIPAL INVESTIGATOR
Innovaderm Research Inc.
Frequently Asked Questions
Who can join the NCT05994976 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acne. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05994976 currently recruiting?
Yes, NCT05994976 is actively recruiting participants. Contact the research team at jbedoucha@innovaderm.com for enrollment information.
Where is the NCT05994976 trial being conducted?
This trial is being conducted at Montreal, Canada.
Who is sponsoring the NCT05994976 clinical trial?
NCT05994976 is sponsored by Innovaderm Research Inc.. The principal investigator is Robert Bissonnette, MD at Innovaderm Research Inc.. The trial plans to enroll 500 participants.